Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Equities research analysts expect that Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) will post earnings of $0.46 per share for the current quarter, according to Zacks. Three analysts have issued estimates for Lantheus’ earnings. The highest EPS estimate is $0.47 and the lowest is $0.45. Lantheus posted earnings of $0.05 per share during the same […]
The consortium will integrate Lantheus' imaging devices and AI platform into its clinical trials to discover novel imaging biomarkers in prostate cancer.
Lantheus and RefleXion Announce Collaboration with Potential to Improve Future Prostate Cancer Treatment itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
Published: Mar 30, 2021
NORTH BILLERICA, Mass. (BUSINESS WIRE) Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from Noria Therapeutics, Inc.
NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting implications in oncology. FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which are believed to modulate tumor progression and immune response. Given its expression in tumors coupled with low expression in normal tissue, FAP has the potential to become an important biomarker for precision medicine in cancer.